***PKTX..PR News Release..
ProtoKinetix AAGP® in Phase 3 Retinal Replacement Program
Press Release |04/23/2019
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix"
KTX) updates its stockholders regarding phase 3 of testing using AAGP® in retinal cell replacement therapy at the University of British Columbia.
The study is now using 2-animal models and a significantly larger number of animals in both control and AAGP® treated groups for a longer time frame. Until this study, the longest a group was tested for was 4-weeks. In this study, the lab currently has animals at the 3-month mark. All animals are reported to be healthy and behaving normally. Early results from this intensive program are expected to be presented to the Company by the end of July 2019. This study is being conducted to test whether AAGP® treated cells continue to develop into retinal cells. If successful, this may potentially lead towards the restoration of vision in humans.
This procedure could become a critical approach for the treatment of retinal diseases including Age-Related Macular Degeneration (AMD). The study is being conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia.
Dr. Gregory-Evans Bio
Dr. Gregory-Evans Video
The global ophthalmic therapeutics/drug market is expected to reach USD $35.7 billion by 2025, according to a new report by Grand View Research, Inc.
The retinal replacement program is just one of several ongoing studies involving our AAGP® molecule. Other ongoing studies are for:
Type one diabetes, islet cell transplants. Currently in clinical trials.
Cord Blood Stem Cell Storage and Recovery.
Cord Blood Stem Cell Transplantation and Engraftment.
Protection and repair of cardiac damage due to toxicity or heart attacks.
Whole organ preservation extending time for human organ transplants.